- Biotech innovation company, Aditxt, Inc (“Aditxt” or the “Company”) is developing and commercializing technologies focused on monitoring and reprogramming the immune system
- Their ground-breaking ADi(TM) immune reprogramming platform will be initially directed towards the treatment of psoriasis, type 1 diabetes and skin allografting
- The Company has also recently begun to commercialize their AditxtScore(TM) proprietary immune mapping technology, which is designed to provide individuals with personalized reports on their immune system
- The AditxtScore(TM) system is initially focused on providing customers with reports looking into their vulnerability and immune response to SARS-CoV-2 and its known variants
Every 9 minutes, a person is placed on an organ transplant waiting list in the United States. Yet, due to a critical shortage of organs, only 41,000 transplantations took place in 2021 (https://ibn.fm/gmVnu). In spite of a wide array of medical innovations in recent years, industry data suggest that approximately 50% of all transplanted organs are rejected by the host’s body within 10-12 years, highlighting the critical need for a practical and cost-effective solution to harmful immune responses. Aditxt (NASDAQ: ADTX) has sought to address this medical conundrum through the creation of immune reprogramming technologies which are being developed to retrain the immune system to induce tolerance to transplanted organs, self-tissues (autoimmune diseases), and allergens.
While still at a pre-clinical stage, ADi(TM) (Apoptotic DNA Immunotherapy), the company’s immune reprogramming platform, looks to address disease-causing immune responses while maintaining the immune system’s ability to combat pathogenic infection and cancer. The technology, which utilizes an approach mimicking the way our bodies naturally induce tolerance to our own tissues, will initially be directed towards treating psoriasis, type 1 diabetes, and skin allografting.
In the interim, Aditxt has recently begun to commercialize its immune mapping technology, AditxtScore(TM), designed to provide individuals with a personalized profile of their immune system. Recent studies related to COVID-19 have shown that contracting the disease can grant the human body some “natural immunity” as reported by researchers at the Johns Hopkins School of Medicine (https://ibn.fm/ICVSa). Nonetheless, the level of immunity may vary significantly from person to person and can wane quickly over time.
With fewer than 70% of Americans fully vaccinated and the prospects of herd immunity becoming less likely, the need to provide individuals with personalized information regarding their immune system has gained increased urgency. Utilizing technology licensed from Stanford University and in partnership with numerous channel partners across the United States, The Company’s AditxtScore(TM) seeks to assist individuals by providing reports looking into their vulnerability and immune status relating to SARS-CoV-2 and its known variants – thus, giving customers the data needed to make informed health decisions. Initially, AditxtScore(TM) will seek to provide individuals with answers to COVID-19 related queries such as:
- Are antibodies present?
- How are these antibodies present – vaccine or natural immune response?
- Will this immunity status provide protection from the virus in the future?
- What is the best approach to creating immunity for that individual?
“As new variants emerge, we want to equip physicians with the most advanced tests that allow a comprehensive view of their patient’s health status,” Kevin Murdock, CEO of Premier Medical Laboratory Services, stated (https://ibn.fm/tD0if). “With AditxtScore(TM), individuals can make more informed decisions about whether vaccination, boosters, or other risk mitigation strategies are the right course of action for them.”
Moving forward, Aditxt anticipates that AditxtScore(TM) may be used across a host of different applications – allowing for early detection of a wide array of conditions, including diabetes, cardio-metabolic illnesses, and hormonal imbalances.
About Aditxt
Aditxt is a biotech innovation company developing and commercializing technologies focused on monitoring and reprogramming the immune system. Aditxt’s immune monitoring technologies are designed to provide a personalized immune profile. Aditxt’s immune reprogramming technologies, currently preclinical, are being developed to retrain the immune system to induce tolerance to address rejection of transplanted organs, autoimmune diseases, and allergies.
For more information, visit the company’s websites at www.Aditxt.com and www.AditxtScore.com.
NOTE TO INVESTORS: The latest news and updates relating to ADTX are available in the company’s newsroom at https://ibn.fm/ADTX
About TinyGems
TinyGems is your guide to the best and brightest in the under-appreciated small-cap sector. As one of 50+ brands within the InvestorBrandNetwork (“IBN”), TinyGems provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions to ensure maximum impact; (4) social media distribution via IBN to reach millions of social media followers; and (5) a full array of corporate communications solutions. It’s time to uncover some of the best-kept secrets on Wall Street. TinyGems features innovative small-cap companies with huge potential, putting a spotlight on the best and brightest of these disruptors that have the technology, the talent, the drive, and the business models to make a huge impact in the markets and in portfolios. Whether it’s a game changing technology, a new more profitable product or service, or a star in a hot sector, TinyGems is the go-to source for actionable intelligence.
To receive SMS text alerts from TinyGems, text “Gems” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.TinyGems.com
Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.com/Disclaimer
TinyGems Los Angeles, California www.TinyGems.com 310.299.1717 Office Editor@TinyGems.com
TinyGems is part of the InvestorBrandNetwork
